To cite this paper use one of the standards below:
The World Health Organization (WHO) estimates that 10-20% of individuals who have had COVID-19 may develop chronic disease, with the likelihood rising to 50-70% among those with moderate to severe cases. This chronic condition, known as post-acute COVID-19 syndrome (PACS), is characterized by the persistence of symptoms and presents significant diagnostic challenges due to its multisystemic nature. Among the affected systems, the cardiovascular system is notably impacted, with the development of cardiovascular diseases being a potential sequel of PACS. However, the cardiovascular pathophysiological mechanisms are not well understood in this syndrome and the parameters related to cardiovascular risk need to be investigated. The present study aims to evaluate cardiovascular risk biomarkers associated with lipid and thromboinflammatory profiles and to investigate their correlation with the development of cardiovascular diseases in PACS. Following approval by the research ethics committee (CAAE 5523520.3.0000.5249), the study included 31 survivors of moderate to severe acute COVID-19 with symptoms lasting from 30 days to 6 months, and 19 control volunteers with negative RT-PCR results for SARS-CoV-2. Lipid profiles were assessed using quantitative colorimetric assays, while thromboinflammatory profiles were analyzed using ELISA technique. The study revealed that survivors exhibited persistent symptoms, particularly those affecting the cardiovascular system. Laboratory results indicated elevated levels of non-HDL-c and LDL-c, alongside increased concentrations of IL-6, IL-1ꞵ, CRP, fibrinogen, and D-dimer, with a concomitant reduction in HDL-c levels. Furthermore, there was an observed increase in cardiovascular indices associated with lipid and thrombotic profiles. Our findings suggest persistent dyslipidemia, systemic inflammation, and hypercoagulability, which may contribute to heightened cardiovascular risk and the pathophysiology of cardiovascular diseases in PACS.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper